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Abstract
Background and objectives: Bupivacaine is a ﬁ rst choice for regional anesthesia considering its 
effectiveness, long duration and less motor blockade. Bupivacaine (S75-R25) is a mixture of 
optical isomers containing 75% levobupivacaine (S-) and 25% dextrobupivacaine (R+) created by 
a Brazilian pharmaceutical company. This investigation compared cardiac safety and efﬁ cacy of 
bupivacaine S75-R25 with vasoconstrictor and ropivacaine for brachial plexus blockade.
Methods: Patients were randomized to receive brachial plexus anesthesia with either bupivacaine 
S75-R25 with epinephrine 1:200,000 (bupi) or ropivacaine (ropi), both at 0.50%, in 30 mL solution. 
We registered a continuous Holter ECG throughout the procedure, as well as the Lovett scale of 
force in addition to monitoring (heart rate, pulse oximetry and non-invasive blood pressure). The 
incidence of adverse events was compared with the chi-square or Fisher test.
Results: We allocated forty-four patients into two groups. They did not show any difference related 
to age, weight or height, gender, as well as for surgical duration. Supraventricular arrhythmias 
were not different before or after the plexus blockade, independent of the local anesthetic 
chosen. Loss of sensitivity was faster for the bupivacaine group (23.1 ± 11.7 min) compared to 
the ropivacaine one (26.8 ± 11.5 min), though not signiﬁ cant (p = 0.205, Student t). There was a 
reduction in the cardiac rate, observed during the twenty-four-hour Holter monitoring.
Conclusions: This study showed similar efﬁ cacy between bupivacaine S75-R25 for brachial plexus 
blockade and ropivacaine, with similar incidences of supraventricular arrhythmias. 
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Bupivacaine has an asymmetric or chiral carbon that gives 
it the property of optical isomers, the form R(+) or dextro-
rotatory and the form S(-) or levorotatory. Local anesthetics 
formulated with bupivacaine use a racemic mixture with 
50% of each of the isomers. Due to its widespread use, 
there were reports of important cardiac and neurological 
toxicity that took place mostly from accidental intravascular 
injections 1.
Drug research introduced two comparable levorotatory 
compounds, the levobupivacaine isomer, a puriﬁ ed (S-) bupi-
vacaine, and the ropivacaine. Clinical studies showed similar 
efﬁ cacy of sensory block for the sciatic nerve 2,3, spinal 
blockade 4-6, and epidural 7,8, both in intensity and duration 
when comparing levobupivacaine with racemic bupivacaine. 
However, its motor blockade seemed inferior 8. Ropivacaine, 
on the other hand, appears to have slightly lower anesthetic 
potency than levobupivacaine or the racemic bupivacaine, 
including a lower motor blockade 8. Ropivacaine reached the 
equivalence of levobupivaine in interscalene brachial plexus 
block 9, and sciatic nerve 3,10. Its cardiac and neurological 
toxicity are apparently lower than the other two anesthet-
ics 11,12. Lethal intravenous doses of levobupivacaine and 
ropivacaine in pigs were equivalent and about two times 
higher than racemic bupivacaine 13. The cardiac toxicity 
induced by intracoronary injection in sheep was similar for 
the three drugs 14. These three drugs produced a QRS widen-
ing in isolated rabbit hearts, and the racemic bupivacaine 
was 2 to 3 times more toxic 15. Also, ropivacaine required a 
higher dose to induce asystole in rats 16.
Levobupivacaine and ropivacaine are less neurotoxic 
than racemic bupivacaine in producing seizures in rats 16,17. 
In sheep, the seizure threshold is always lower among the 
pregnant animals. Ropivacaine is safer than levobupivacaine, 
which in turn is safer than bupivacaine 18.
Although in vitro studies have shown that the two isomers 
of bupivacaine are equipotent in promoting motor block 19, 
the dextrorotatory form is more potent than the levorotatory 
in inhibiting sodium channels 20, which justiﬁ es a reduced 
motor block when using the mixture with a higher concen-
tration of the isomer (S-). Brazilian pharma introduced an 
enantiomeric mixture of optical isomers containing 75% of 
levobupivacaine (S-) and 25% of dextrobupivacaine (R+), 
a bupivacaine (S75-R25). Studying the effectiveness of 
levobupivacaine and the bupivacaine (S75-R25) in epidural 
anesthesia, we found a reduction in the incidence of cardiac 
and neurological adverse events and the adequacy of sensory 
and motor blockade 21,22. 
This study compared cardiac safety and efficacy of 
anesthetic bupivacaine S75-R25 with vasoconstrictor and 
ropivacaine for brachial plexus blockade (BPB) for upper limb 
surgery, considering the technique may infuse large doses 
of local anesthetic.
Methods
After approval from the Ethical Review Board, patients of 
both sexes aged between 18 and 40 years with an indication 
for elective unilateral forearm,  wrist or hand procedures 
were invited to participate. They constituted a convenience 
sample with group allocation determined by a computerized 
table to receive either bupivacaine S75-R25 (bupi group) or 
ropivacaine (ropi group).
According to the American Society of Anesthesiologists 
(ASA), all patients were considered ASA I or II. Those showing 
local anesthetic hypersensitivity, intolerance or allergy to any 
of the drugs used in this protocol, as well as patients with 
multiple trauma or acute injuries like spinal cord injuries, 
peripheral neuropathy or other neurological disorders were 
excluded. Exclusion criteria have also been myocardial infarc-
tion less than 6 months prior, dementia and other cognitive 
matter, abuse of alcohol and antiretroviral drug use. We 
excluded patients who signed the consent but would show 
any signiﬁ cant changes in the baseline Holter monitoring, 
an hemoglobin < 10 g.dL-1, leukocytosis higher than 14,000; 
an INR > 1.3, persistent atrial ﬁ brillation or the presence of 
ventricular extrasystoles.
We used the “Holter” ECG GE model MARS 5000. The 
Visual Analog Scale (VAS) for pain assessed patients in the 
postoperative 23,24. The Lovett scale of force was used to as-
sess strength, based on subjective evaluation with 6 degrees 
(6 – Normal: force; 5 - Good: muscle wins gravity but strength 
is reduced; 4 - Reasonable: the muscle is able to overcome 
gravity and perform partially normal movements; 3 - Weak: 
small movements can be executed but do not win gravity; 
2 - Trait: there is muscle contraction but no movement; 1 - 
Paralysis: no contraction or movement is observed).
After the consent and one week before patients col-
lected laboratory exams, a resting ECG was registered and 
they were placed in Holter monitoring (preop) to capture 
a baseline tracing. The perioperative Holter monitoring 
(postop) was installed in the operating room. We used the 
following monitoring devices: pulse oximeter, non-invasive 
arterial pressure monitor and electrocardiography. A nasal 
cannula for administration of oxygen (2 L.min-1) was offered. 
Patients received midazolam 0.05 to 0.3 mg.kg-1 (maximum 
at 15 mg) intramuscular before the procedures.
The axillary artery was identiﬁ ed by palpation, followed 
by the insertion of the electrically isolated needle on the 
medial side of the arm in a 45-degree angle to the skin. 
Electrical stimulation pulses with a duration of 0.1 - 0.2 ms, 
frequency 1 to 2 Hz were used to promote motor response in 
order to guide the progression and direction of the needle. 
After the identiﬁ cation of suitable location for the injection 
of local anesthetics in territories of nerves radial, median 
and musculocutaneous, a test for the prevention of intra-
vascular injection with 3 mL of sodium chloride with 15 mcg 
of adrenaline was done.
Patients received an inﬁ ltration of 30 ml of anesthetic - 
either the bupivacaine S75-R25 solution at 0.50% (bupi) or 
ropivacaine at 0.50% (ropi), according to protocol selection 
of unidentiﬁ ed ampoules. These were prepared as 20 mL of 
ropivacaine and 20 mL of bupivacaine S75-R25 with epineph-
rine 1:200,000, that remained sealed throughout the study 
and were open only after collecting all information from 
medical records. Whenever a partial failure was detected, 
the protocol allowed the use of fentanyl 1 mcg.kg-1 and a 
continuous target-infusion of propofol of up to 3 mcg.mL-1, 
both intravenously. In the case of total failure, the procedure 
would be directed to general anesthesia. 
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The following parameters were evaluated every ﬁ ve min-
utes: skin conductance by patch clamping, motor blockade 
(Lovett), heart rate, blood pressure and hemoglobin satura-
tion (oximeter). After 30 minutes of blockade inﬁ ltration, 
if there was a partial or total failure of anesthesia, the 
anesthesiologist had to decide the procedure to be adopted 
and the data collected were discarded as not suitable for 
the investigation. Patients received 100 mg of ketoprofen 
and 2,000 mg of dipyrone right after the end of surgery and 
tramadol 100 mg was prescribed on demand. They were as-
sessed after six and 24 hours of injection of the anesthetic, 
when the Holter was removed and the patient questioned 
about adverse events and tolerability.
Statistical analysis was done using STATISTICA version 5.0 
(Statsoft Inc, Tulsa, USA) with a signiﬁ cance level of 0.05. 
Quantitative variables are represented by mean and standard 
deviation, median and minimum and maximum values, com-
pared by analysis of variance with repeated measures. We 
represent qualitative variables such as incidence of adverse 
events with absolute (n) and relative (%) numbers, compared 
using the chi-square or Fisher test.
Results
Forty-four patients signed the informed consent and were 
allocated into the two groups. They did not show any differ-
ence related to age, weight, height, or gender nor in surgical 
duration (Table 1). The procedures performed - arthrodesis 
and arthroplasty, neurolysis, Kirschner wire removal, tenoly-
sis, fracture ﬁ xation and carpal tunnel release surgery - were 
fairly distributed among the two groups. Both groups lost one 
patient’s data due to inappropriate Holter records.
All patients showed responses related to electrical 
stimulation of nerves radial, median and musculocutane-
ous. They have their heart rate reduced from preoperative 
measurements compared to surgery under the brachial plexus 
blockade (p < 0.0001), a reduction that was not different 
between the groups (p = 0.997). The number of QRS complex 
was also reduced (p < 0.0001) from preoperative during the 
surgery, but was not different between the groups (p = 0.585). 
Independent of which local anesthetic was used, the number 
of supraventricular arrhythmias was not different before or 
after the plexus blockade. The differences among these re-
sults showed a lower heart rate, a lower maximum heart rate, 
a reduced number of QRS. The number of supraventricular 
arrhythmias remained the same (Table 2).
The loss of sensitivity was faster for the bupivacaine (23.1 
± 11.7 min) compared to the ropivacaine group (26.8 ± 11.5 
min), though not signiﬁ cant (p = 0.205, Student t). Motor 
blockade was signiﬁ cantly lower (better level of block) among 
patients under bupivacaine from the 35th minute and beyond. 
Two patients from the bupivacaine group and four from the 
ropivacaine experienced insufﬁ cient anesthetic blockade 
(p = 0.66, Chi-square), receiving propofol (bupivacaine, 
n = 7; ropivacaine, n = 3) and/or fentanyl (bupivacaine, n = 
4; ropivacaine, n = 1). Four patients from the bupivacaine 
Table 1 – Patient characteristics and surgery duration (min) (mean ± SD).
Bupivacaine S75-R25 
(n = 22)
Ropivacaine
(n = 22)
p value
Age 40.6 ± 11.4 40.9 ± 11.3 0.936*
Weight 78.7 ± 19.2 72.6 ± 15.5 0.254*
Height 1.70 ± 0.10 1.60 ± 0.10 0.070*
BMI 27.6 ± 6.7 27.1 ± 5.6 0.795*
Surgery duration 74.5 ± 51.8 94.5 ± 53.1 0.211*
Gender (male/female) 9/13 7/15 0.754**
*Student t; ** Chi-Square.
Table 2 – Holter (mean ± SD).
Bupivacaine S75-R25
 (n = 21)
Ropivacaine
(n = 21)
p value
Heart rate
preoperative 81.3 ± 10.7 84.9 ± 9.4
0.997
postoperative 72.4 ± 8.0 68.5 ± 10.9
P < 0.0001 ANOVA
QRS (n)
preoperative 4,660.5 ± 545.6 4,726.3 ± 541.3
0.585
postoperative 4,277.2 ± 502.8 4,037.1 ± 668.3
p < 0.0001 ANOVA
SV arrhythmias (n)
preoperative 2.0 0.0 0.659
postoperative 1.0 1.0 0.163
p = 0.139 p = 0.916 M-W
Pre-Intra Diff M-W
Heart Rate 8.9 ± 7.3 19.3 ± 9.1 0.005
Maximum HR 14.3 ± 10.8 18.1 ± 7.7 0.045
QRS 383.3 ± 357.9 689.2 ± 590.2 0.045
SV arrhythmias -3.7 ± 8.8 -0.1 ± 4.6 0.339
SV: Supraventricular; M-W: Mann-Whitney; HR: heart rate; Diff: difference.
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group requested tramadol during the postoperative period, 
whereas seven did so in the ropivacaine group (p = 0.48, 
Chi-square) (Table 3).
Discussion
This study showed a similar efﬁ cacy of bupivacaine S75-R25 
with epinephrine and ropivacaine in brachial plexus block, 
without a higher incidence of supraventricular arrhyth-
mias and a reduced cardiac rate during a 24-hour Holter 
monitoring.
Although the advantages of upper extremity blockade 
are well established, the cardiotoxicity is, perhaps, the most 
severe complication associated with the use of long-acting 
local anesthetics. A previous study of interscalene BPB with 
patients under a holter monitoring showed prolongation of 
PQ interval with racemic bupivacaine, but not with ropiva-
caine 25. Also, no cardiovascular toxicity – such as changes 
in QRS complex, PQ interval and AV dissociation – was reg-
istered with a combination of prilocaine and ropivacaine in 
the blockade 26.
The anesthetic efﬁ cacy of levobupivacaine in BPB has 
been reportedly similar to the racemic bupivacaine for la-
tency, failure rate, and motor blockade 27. In addition, both 
anesthetics offered prolonged postoperative analgesia com-
pared to ropivacaine for BPB and for femoral nerve block, al-
though ropivacaine block installed faster 28. Notwithstanding, 
the literature seems to have no register of studies addressing 
cardiovascular toxicity with levobupivacaine during a brachial 
plexus blockade.
This report showed that both bupivacaine S75-R25 and 
ropivacaine had a comparable mean time to promote anes-
thesia. The motor blockade reached the “trace” level in the 
Lovett scale (evidence of slight contractility) faster with ropi-
vacaine. This ﬁ nding was in accordance with a previous report 
suggesting ropivacaine to be a faster anesthetic drug 28, and 
with a slightly better sensory as well as motor blockade than 
levobupivacaine, while duration was similar 29.
Four patients that received ropivacaine and two that 
received bupivacaine S75-R25 had partial incomplete block-
ade. All of them were treated with 100 mcg of fentanyl 
intravenously and a target-infusion propofol. Compared to 
the bupivacaine S75-R25 blockade (8.9 ± 7.3), patients in the 
ropivacaine group also showed a higher reduction in cardiac 
rate during surgery in relation to the preoperative measure-
ment (19.3 ± 9.1). It is also interesting to notice that both 
systolic (136.8 ± 17.4 vs 126.7 ± 16.2) and diastolic pressure 
(76.9 ± 11.8 vs 69.1 ± 8.7) were higher with ropivacaine. 
These results suggest that both ropivacaine and bupivacaine 
S75-R25 are good options for BPB having the advantage of 
a low cardiotoxicity. They may also be adequate for hyper-
tensive patients, since regional anesthesia could prevent 
the “tourniquet hypertension”, although ropivacaine may 
otherwise bring some additional risk of not counteracting 
this phenomenon 30,31. 
Finally, a limitation in this research was the lack of follow-
up for analgesia duration with the use of a visual analogic 
scale. Nevertheless, a previous study with equal masses of 
ropivacaine and levobupivacaine suggested the latter may 
reach a greater duration of sensory analgesia - up to 15 hours 
- but with a longer motor blockade 32. There was no consump-
tion of non-steroidal analgesics during post-anesthesia care 
unit, as well as no register of post-operative nausea or vomit-
ing, even with a similarly lower demand for tramadol.
In conclusion, this study suggests both bupivacaine 
S75-R25 and ropivacaine were not associated with cardiac 
toxicity during brachial plexus blockade within 24 hours of 
surveillance, but it seems advisable to point out that ropiva-
caine should be under careful consideration for hypertensive 
patients.
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